Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2009. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing discloses the Company's issued share capital as of November 30, 2009:
- Total Issued Ordinary Shares: 5,663,589,129 (25p each with voting rights).
- Treasury Shares: 474,194,158 Ordinary shares.
- Total Voting Rights: 5,189,394,971.
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the calculation of voting rights for shareholder notification purposes under Financial Services Authority rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,189,394,971) as the denominator for calculating disclosure thresholds under Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (474,194,158) which are excluded from the voting rights total.
- Note that this filing does not contain operational or financial performance results for the period.